BRIN E FREUND M.D.
Prescription History 1093151813
Psychiatry & Neurology - Epilepsy
in Jacksonville, FL
NPI Status: Active since May 20, 2013
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for BRIN E FREUND M.D., an active Epilepsy specialist practicing in Jacksonville, FL. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 36 documented patient claims. Among these therapy options, the most frequently utilized medication is Lacosamide, which accounts for 14 claims alone.
Lacosamide
Generic Formulation: LacosamideSpecialty: NeurologyProvider Avg Cost Per Claim
$231.29
State Avg Cost Per Claim
$364.95
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.
Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.
Levetiracetam
Generic Formulation: LevetiracetamSpecialty: NeurologyProvider Avg Cost Per Claim
$105.15
State Avg Cost Per Claim
$41.28
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.
Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.
Xcopri
Generic Formulation: CenobamateSpecialty: NeurologyProvider Avg Cost Per Claim
$1,299.38
State Avg Cost Per Claim
$1,270.94
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This medication is used to treat a certain type of seizure disorder (partial onset). It is not known exactly how it works, but it may affect the action of some nerves that cause seizures.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like BRIN E FREUND M.D. provides transparency into local medical care patterns within Jacksonville, FL.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Epilepsy ** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
